NVP-HDM201 is primarily investigated for its potential in cancer therapy, particularly in targeting cancers driven by p53 mutations. It functions as a MDM2 inhibitor, which helps in reactivating the p53 tumor suppressor pathway, leading to the induction of apoptosis in cancer cells. This makes it a promising candidate for treating various malignancies, including hematologic cancers and solid tumors. Research is ongoing to evaluate its efficacy in combination with other therapeutic agents to enhance cancer treatment outcomes.